US4670245A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Diagnostic procedures using radiolabeled colloidal bismuth subcitrate and related compounds
Assignee: Individual
•
Filing: 1984-04-27
•
Granted: 1987-06-02
•
Expires: 2004-04-27
Abstract
Abstract An unusual diagnostic procedure for the in vivo clinical evaluation of gastrointestinal ulcer disease and other diseases associated with loss of mucosal integrity in both animals and humans which comprises the oral administration of an effective amount of radiolabeled colloidal bismuth subcitrate or other ulcer avid bismuth compound to an animal or human host, followed by scintigraphic imaging of the gastrointestinal area of interest with scintigraphic imaging equipment. Also disclosed is a novel radiopharmaceutical composition comprising an aqueous solution or suspension containing an amount of a radiolabeled bismuth-protein complex effective for in vivo scintigraphic imaging of the gastrointestinal or other mucosal areas in animals and humans.
Inventors
- 👤 Tony E. Vasquez
- 👤 Kenneth P. Lyons
- 👤 Moussa Raiszadeh
- 👤 Manouchehre Fardi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 08:09
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/12; A61K51/1217; A61K2123/00
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
49 words
A diagnostic procedure for the in vivo clinical evaluation of gastrointestinal ulcer disease and other diseases associated with loss of mucosal integrity, comprising: orally administering an effective amount of a radiolabeled ulcer-avid bismuth-protein complex to a subject; and imaging the gastrointestinal area of the subject with scintigraphic imaging equipment.
Claim 2
Dependent Claim
49 words
A diagnostic procedure for the in vivo clinical evaluation of gastrointestinal ulcer disease and other diseases associated with loss of mucosal integrity, comprising: orally administering an effective amount of a radiolabeled ulcer-avid bismuth-protein complex to a subject; and imaging the gastrointestinal area of the subject with scintigraphic imaging equipment.
Claim 3
Dependent Claim
24 words
The procedure of claim 1, further comprising the step of combining a bismuth compound or ion with a protein to form the bismuth-protein complex.
Claim 4
Dependent Claim
68 words
The procedure of claim 2, wherein the bismuth compound or ion is selected from the group consisting of colloidal bismuth subcitrate, Bi(C 6 H 5 O 7 ) 2 -3 , Bi(C 6 H 5 O 7 ), Bi 2 O 3 , BiO + , BiOCl, BiCl 3 , BiCl 4 - , BiCl 2 + , bismuth ammonium citrate, a bismuth subcitrate-peptide complex, and bismuth gallate.
Claim 5
Dependent Claim
17 words
The procedure of claim 2, further comprising the step of labeling said protein with a medical radionuclide.
Claim 6
Dependent Claim
14 words
The procedure of claim 1, wherein the complex is labeled with Technetium-99m or Iodine-123.
Claim 7
Dependent Claim
22 words
The procedure of claim 1, wherein the radiolabeled complex is prepared by combining colloidal bismuth subcitrate with radiolabeled protein under acidic conditions.
Claim 8
Dependent Claim
10 words
The procedure of claim 6, wherein the protein is albumin.
Claim 9
Dependent Claim
13 words
The procedure of claim 1 wherein the complex contains a colloidal bismuth salt.
Claim 10
Dependent Claim
4 words
Radiolabeled colloidal bismuth subcitrate.
Claim 11
Dependent Claim
4 words
Radiolabeled colloidal bismuth subcitrate.
Claim 12
Dependent Claim
8 words
A radiopharmaceutical composition, comprising a radiolabeled bismuth-protein complex.
Claim 13
Dependent Claim
8 words
A radiopharmaceutical composition, comprising a radiolabeled bismuth-protein complex.
Claim 14
Dependent Claim
17 words
The composition of claim 10, wherein the complex is formed of colloidal bismuth subcitrate and radiolabeled albumin.
Claim 15
Dependent Claim
59 words
A kit for making a radiolabeled bismuth-protein complex suitable for imaging ulcers and other conditions associated with loss of mucosal integrity in the upper gastrointestinal tract when orally administered to a patient, comprising a container of rehydratable lyopholized bismuth salt-protein complex, wherein said lyopholized complex, upon rehydration with a solution containing a medical radionuclide, becomes labeled with said radionuclide.
Claim 16
Dependent Claim
59 words
A kit for making a radiolabeled bismuth-protein complex suitable for imaging ulcers and other conditions associated with loss of mucosal integrity in the upper gastrointestinal tract when orally administered to a patient, comprising a container of rehydratable lyopholized bismuth salt-protein complex, wherein said lyopholized complex, upon rehydration with a solution containing a medical radionuclide, becomes labeled with said radionuclide.
Claim 17
Dependent Claim
12 words
The kit of claim 12, wherein the bismuth salt is bismuth subcitrate.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-06-01 | 1990-12-01 | 1991-06-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-06-01 | 1994-12-01 | 1995-06-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-06-01 | 1998-12-01 | 1999-06-02 | $7700.00 | Window Closed / Lapsed |